Daily briefing: Gene-therapy deaths put spotlight on trials in China

Nature正文已收录本站
  • NATURE BRIEFING

The deaths of two children in separate gene-therapy trials could have a profound effect on China’s biomedical industry, say researchers. Plus, an AI system has formalized Fermat’s last theorem and the impact of Nancy Grace Roman.

Hello Nature readers, would you like to get this Briefing in your inbox free every day? Sign up here.

Andrew Wiles posing next to Fermat’s last theorem, written in white chalk on a blackboard.kboard

Mathematician Andrew Wiles completed his proof of Fermat’s last theorem in 1994, more than 350 years after Pierre Fermat proposed it.Credit: AP Photo/Charles Rex Arbogast/Alamy

AI formalizes Fermat’s last theorem

An advanced prototype of the artificial-intelligence chatbot Claude has produced a 13-million-line, computer-checked proof of Fermat’s last theorem in just 11 days. That a machine could formalize the landmark proof — a project that was expected to take humans around a decade — “just completely blew my mind”, says number theorist Alex Kontorovich. The result shows that AI will play an increasingly important part in creating algorithmically checkable versions of mathematicians’ work, and hints that such technology could soon scrutinize the entire library of mathematical knowledge.

Nature | 5 min read

Reference: Anthropic announcement

Almost half of farmers are being poisoned

There are more than 400 million cases of unintentional, acute pesticide poisoning every year, finds a new estimate — meaning that an estimated 46% of farmers worldwide are being poisoned. The analysis suggests there are 11,000 pesticide-related deaths annually, with nearly 60% of these in India. And that’s not taking into account long-term health impacts that are not immediately felt, such as a possible link with Parkinson’s disease.

The Guardian | 6 min read

Reference: Frontiers in Public Health paper

Clinical trials in China

Gene-therapy deaths put spotlight on trials

The deaths of two children in separate gene-editing trials in China raise questions about oversight and could have a profound effect on the country’s biomedical industry, say researchers, ethicists and legal scholars. The two trials involved breaches of ethics and lacked transparency, and the deaths — one of which was only revealed after an investigation by Science and Retraction Watch — will probably prompt the introduction of stronger regulations for gene-therapy trials, researchers say. But a balance must be struck, says legal scholar Hank Greely. “We can’t make ethics so tight that no research can ever possibly be done,” he says.

Both trials fast-tracked as investigator-initiated trials (IITs). These enable researchers in China to test therapies quickly without supervision from the country’s drug regulator, and are widely considered to be a driving force behind China’s rising competitiveness in biomedicine. News of the deaths comes only months after the government introduced stricter rules for IITs of new biomedical technologies, which mandate that only certain hospitals may host such trials and which grant regulatory agencies the power to suspend or terminate trials if there are technical or ethical concerns.

Nature | 9 min read & Nature | 5 min read

Image of the week

Filmed from above, an armoured searobin boogies across the sea floor.

This deep-sea fish, spotted by researchers in the northern South China Sea, can do a wicked moonwalk. The armoured searobin (Scalicus engyceros) “boasts a striking shrimp–fish hybrid body appearance”, says marine researcher and study co-author Han Tian. And it can walk sideways and even backward, a movement that has never been observed in other fishes. (The Independent | 5 min read)

Reference: Ocean-Land-Atmosphere Research paper (Kedong Yin)

Features & opinion

Lessons from a biobank data leak

In April, the UK Biobank — one of the largest and most comprehensive health-tracking studies in the world — fell victim to what appeared to be a massive data leak, with data on hundreds of thousands of participants available for sale on the internet. The open nature of this world-leading health-dataset has made it valuable to researchers, but also vulnerable. Now, as the resource plans to begin reopening, scientists are getting a glimpse of how it will try to tighten security, and what impacts that will have on the research.

Nature | 10 min read

Roman is ‘reminder of a true space pioneer’

The Nancy Grace Roman Space Telescope, which launched on 30 August, is named after NASA’s first chief astronomer. The era that she led — the emergence of space astronomy in the 1950s and 1960s — created “arguably the most remarkable transformation” in the history of astronomy, writes historian Robert Smith. She set the wheels in motion for the triumph of the Hubble Space Telescope in the face of doubts, including those from ground-based astronomers and from NASA scientists who felt they’d been missold the scientific value of the Apollo Moon missions.

Nature | 7 min read

What do we owe the future?

“A truly flourishing society is one that not only lifts people out of poverty today but also passes on the capital — produced, human and natural — that allows future generations to flourish, too,” writes economist Eoin McLaughlin. He argues that questions about how to revise measures of prosperity, such as gross domestic product (GDP), would do better to focus on whether governments are leaving behind more or less wealth for those who come after us.

Nature | 14 min read

Quote of the day

doi: https://doi.org/10.1038/d41586-026-02838-1

This newsletter is always evolving — tell us what you think! Please send your feedback to briefing@nature.com.

Thanks for reading,

Flora Graham, chief editor, Nature Briefing

With contributions by Jacob Smith

• Nature Briefing: Careers — insights, advice and award-winning journalism to help you optimize your working life

• Nature Briefing: Microbiology — the most abundant living entities on our planet — microorganisms — and the role they play in health, the environment and food systems

• Nature Briefing: Anthropocene — climate change, biodiversity, sustainability and geoengineering

• Nature Briefing: AI & Robotics — 100% written by humans, of course

• Nature Briefing: Cancer — a weekly newsletter written with cancer researchers in mind

• Nature Briefing: Translational Research — covers biotechnology, drug discovery and pharma

  • Daily briefing: Bunsen burners don’t waft bacteria away from workbenches

  • Daily briefing: Psilocybin blocks side-effect of chemotherapy in mice

  • Daily briefing: GLP-1 obesity drugs slow signs of ageing in mice

  • Daily briefing: A thrilling hint of dark matter discovery